Anthropometric risk factors for ovarian cancer in the NIH-AARP Diet and Health Study.
Adiposity
Body fat
Obesity
Ovarian cancer risk
Journal
Cancer causes & control : CCC
ISSN: 1573-7225
Titre abrégé: Cancer Causes Control
Pays: Netherlands
ID NLM: 9100846
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
01
09
2020
accepted:
25
11
2020
pubmed:
23
1
2021
medline:
20
4
2021
entrez:
22
1
2021
Statut:
ppublish
Résumé
Identifying potentially modifiable risk factors for ovarian cancer is essential for prevention because this cancer is predominantly detected at a late stage. Here, we estimated the relations of general adiposity and measures reflecting body fat distribution to the risk of epithelial ovarian cancer. We ascertained 683 ovarian epithelial cancers (343 high-grade serous, 141 non-high grade serous) among 145,575 women, aged 50-72 years (median follow-up 12.6 years), from the National Institutes of Health-American Association of Retired Persons (NIH-AARP) Diet and Health Study. Using Cox models, we estimated confounder-adjusted hazard ratios (HRs) and 95% confidence intervals (CI) for associations of overall ovarian cancer, high-grade serous and non-high-grade serous carcinoma with body mass index, waist circumference, hip circumference, waist-hip ratio, waist-height ratio, body adiposity index, body shape index, and abdominal volume index. Anthropometric measures were unrelated to overall ovarian cancer, high-grade serous cancer, and non-high-grade serous cancer. For example, the HR for overall ovarian cancer per standard deviation increment of body mass index at baseline was 0.98 (95% CI 0.88-1.10). Similar associations were observed with measurements of body fat distribution. These results do not indicate that adult adiposity is associated with ovarian cancer risk in post-menopausal women.
Identifiants
pubmed: 33481137
doi: 10.1007/s10552-020-01377-y
pii: 10.1007/s10552-020-01377-y
pmc: PMC7870624
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
231-239Références
Eur J Epidemiol. 2019 Mar;34(3):211-219
pubmed: 30840181
Eur J Clin Invest. 2017 Jun;47(6):415-421
pubmed: 28380255
Scand J Public Health. 2018 Jul;46(5):565-579
pubmed: 29528773
Br J Cancer. 2013 Aug 6;109(3):751-5
pubmed: 23860524
Stat Med. 2014 May 30;33(12):2137-55
pubmed: 24497385
Int J Epidemiol. 2016 Jun;45(3):884-95
pubmed: 27401727
BMJ. 2017 Oct 26;359:j4511
pubmed: 29074629
J Clin Oncol. 2016 Aug 20;34(24):2888-98
pubmed: 27325851
J Natl Cancer Inst. 2015 Mar 10;107(2):
pubmed: 25757865
Br J Cancer. 2019 Jul;121(2):180-192
pubmed: 31213659
Stat Med. 2005 Feb 15;24(3):479-89
pubmed: 15532086
Cancer Biol Med. 2017 Feb;14(1):9-32
pubmed: 28443200
Cancer Causes Control. 2018 Feb;29(2):201-212
pubmed: 29327114
PLoS One. 2012;7(7):e39504
pubmed: 22815707
Ann Oncol. 2019 Feb 1;30(2):303-309
pubmed: 30576422
Pathobiology. 2018;85(1-2):41-49
pubmed: 29020678
Cancer Epidemiol. 2016 Apr;41:8-15
pubmed: 26775081
Am J Epidemiol. 2001 Dec 15;154(12):1119-25
pubmed: 11744517
Epidemiology. 2016 Mar;27(2):302-10
pubmed: 26628428
Obesity (Silver Spring). 2007 Jan;15(1):188-96
pubmed: 17228047
Nat Rev Dis Primers. 2016 Aug 25;2:16061
pubmed: 27558151
Br J Cancer. 2017 May 23;116(11):1486-1497
pubmed: 28441380
Int J Cancer. 2015 Apr 15;136(8):1888-98
pubmed: 25250505
Int J Cancer. 2010 May 15;126(10):2404-15
pubmed: 19821492
Int J Obes (Lond). 2018 Oct;42(10):1762-1770
pubmed: 30120428
Endocr Relat Cancer. 2013 Mar 22;20(2):251-62
pubmed: 23404857
Obesity (Silver Spring). 2011 May;19(5):1083-9
pubmed: 21372804
BMJ. 2017 Feb 28;356:j477
pubmed: 28246088
Epidemiology. 1990 Nov;1(6):466-73
pubmed: 2090285
Stat Med. 2002 Aug 15;21(15):2175-97
pubmed: 12210632
Int J Cancer. 2015 Oct 1;137(7):1699-708
pubmed: 25810218